These randomized controlled trials strongly support the use of SGLT2 inhibitors to reduce ALT and AST levels and improve liver fibrosis in patients with T2DM and NAFLD. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.